What is the price targets for Vertex Pharmaceuticals (VRTX) stock?
Their VRTX stock forecasts range from $222.00 to $365.00. On average, they expect Vertex Pharmaceuticals' share price to reach $287.68 in the next year. This suggests a possible upside of 2.6% from the stock's current price. View analysts' price targets for Vertex Pharmaceuticals or view top-rated stocks among Wall Street analysts.
How much has Ventrix’s executive team been growing?
Chief Medical Officer To view Ventrix’s complete executive team members history, request access » Ventrix Signals Growth Rate 0.80%Weekly Growth Weekly Growth0.80%, 93rd % -35.5%.530% Size Multiple 219xMedian
What are analysts'price targets for Vertiv's stock?
6 analysts have issued twelve-month price objectives for Vertiv's stock. Their forecasts range from $25.00 to $35.00. On average, they expect Vertiv's share price to reach $30.00 in the next twelve months. This suggests a possible upside of 24.6% from the stock's current price.
Is Vertiv (vet) stock a buy or sell?
Vertiv has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings. According to analysts' consensus price target of $30.00, Vertiv has a forecasted upside of 25.3% from its current price of $23.94.
We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate
Ventyx Biosciences Announces First Patient Dosed in a Phase 2 Clinical Trial of VTX002 for the Treatment of Moderate-to-Severe Ulcerative Colitis
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
VTX002 is an oral, peripherally-restricted, selective sphingosine 1 phosphate receptor 1 (S1P1) receptor modulator internally discovered and developed by the team at VentyxENCINITAS, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc.
When will Vertex Pharmaceuticals buy back its stock?
ENCINITAS, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc.
What is the NASDAQ symbol for Vertex Pharmaceuticals?
How will Vertex Pharmaceuticals' stock buyback program work? Vertex Pharmaceuticals declared that its board has approved a stock repurchase program on Wednesday, July 31st 2019 , which authorizes the company to buyback $500,000,000.00 in shares, according to EventVestor.
How much does Vertex Pharmaceuticals make?
Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."
What is the official website of Vertex Pharmaceuticals?
Vertex Pharmaceuticals has a market capitalization of $51.90 billion and generates $6.21 billion in revenue each year. The pharmaceutical company earns $2.71 billion in net income (profit) each year or $9.03 on an earnings per share basis.
What is Vertex Pharmaceuticals?
The official website for Vertex Pharmaceuticals is www.vrtx.com.
Does Vertex Pharmaceuticals pay dividends?
Vertex Pharmaceuticals, Inc. is a global biotechnology company. It engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Will VTRIX outperform in future?
Vertex Pharmaceuticals does not currently pay a dividend.
Balanced subadvisor lineup aided by low fees
Get our overall rating based on a fundamental assessment of the pillars below.
Recently Viewed Tickers
Vanguard International Value unites three complementary strategies into a single low-cost offering. It earns a Morningstar Analyst Rating of Bronze, a downgrade from Silver as competition increased within the Morningstar Category.
Venator Materials PLC
Visit a quote page and your recently viewed tickers will be displayed here.
Who bought Vertiv stock?
Venator Materials Plc engages in the manufacture and marketing of chemical products. The firm focuses on development and manufacture of titanium dioxide pigments and performance additives. It operates through two segments: Titanium Dioxide and Performance Additives.
What is Vertiv Holdings?
VRT stock was acquired by a variety of institutional investors in the last quarter, including TCW Group Inc., and Rheos Capital Works Inc.. Company insiders that have bought Vertiv stock in the last two years include Colin Flannery, and Edward L Monser.
What is the symbol for Vertiv?
engages in the design, manufacturing, and service of critical digital infrastructure technology that powers, cools, deploys, secures and maintains electronics that process, store and transmit data. It also offers power management products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It carries out its operations in the following segments: Americas, Asia Pacific, and Europe, Middle East & Africa (EMEA). The Americas segment offers critical infrastructure and solutions, integrated rack solutions, and services and spares. The Asia Pacific segment includes products and services sold for applications within the data center, communication networks and commercial or industrial markets throughout China, India, and the rest of Asia. The EMEA segment sells products and services for applications within the data center, communication networks and commercial/industrial markets. The company was founded on February 7, 2020 and is headquartered in Columbus, OH.
What is the rating of Vertiv?
Vertiv trades on the New York Stock Exchange (NYSE) under the ticker symbol "VRT."
Where is Vertiv located?
Vertiv has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Does Vertiv have a long track record of dividend growth?
Vertiv's mailing address is 1050 DEARBORN DRIVE, COLUMBUS OH, 43085. The company can be reached via phone at (614) 888-0246 or via email at [email protected].
